Insulet (NASDAQ:PODD) Given New $171.00 Price Target at UBS Group

Insulet (NASDAQ:PODD) had its target price upped by investment analysts at UBS Group from $150.00 to $171.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage presently has a “neutral” rating on the medical instruments supplier’s stock. UBS Group‘s price target points to a potential upside of 9.53% from the company’s current price.

PODD has been the topic of a number of other research reports. Sanford C. Bernstein increased their price target on Insulet from $175.00 to $200.00 and gave the company an “outperform” rating in a research note on Thursday. Citigroup lifted their price target on Insulet from $150.00 to $170.00 and gave the company a “neutral” rating in a research note on Thursday. Leerink Partners increased their target price on Insulet from $143.00 to $167.00 and gave the company a “market perform” rating in a research report on Thursday. Barclays upgraded shares of Insulet to a “hold” rating in a research report on Wednesday, October 7th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $200.00 target price on shares of Insulet in a research note on Wednesday. Thirteen equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $192.36.

Insulet Stock Down 5.4%

Shares of PODD stock traded down $8.90 on Thursday, hitting $156.12. 1,319,217 shares of the stock were exchanged, compared to its average volume of 1,397,991. The firm has a market capitalization of $10.83 billion, a P/E ratio of 29.18, a price-to-earnings-growth ratio of 1.22 and a beta of 1.06. The business has a 50-day moving average of $141.65 and a 200 day moving average of $178.00. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. Insulet has a fifty-two week low of $126.40 and a fifty-two week high of $354.88.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.59 by $0.40. The business had revenue of $842.00 million for the quarter, compared to the consensus estimate of $832.63 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%. Insulet’s quarterly revenue was up 19.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.24 earnings per share. Equities analysts anticipate that Insulet will post 6.51 EPS for the current year.

Institutional Investors Weigh In On Insulet

A number of institutional investors have recently added to or reduced their stakes in the company. Elevation Wealth Partners LLC increased its position in shares of Insulet by 115.6% during the third quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 104 shares during the last quarter. Activest Wealth Management raised its position in shares of Insulet by 186.3% in the third quarter. Activest Wealth Management now owns 229 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 149 shares during the period. WPG Advisers LLC lifted its position in shares of Insulet by 169.3% during the third quarter. WPG Advisers LLC now owns 272 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 171 shares in the last quarter. State of Wyoming lifted its holdings in Insulet by 34.6% during the 1st quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock worth $60,000 after purchasing an additional 73 shares in the last quarter. Finally, Continuum Advisory LLC bought a new position in shares of Insulet in the second quarter valued at approximately $46,000.

Insulet News Summary

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported Q3 adjusted EPS of $1.99, above the $1.59 consensus, while revenue rose 19.2% year over year to $842 million and also topped estimates. The company announced a $1 billion share-repurchase program and updated its 2026 outlook. Insulet Q3 earnings and revenue beat
• Positive Sentiment: Several analysts lifted their price targets after the results. Bernstein raised its target to $200 and kept an outperform rating; RBC raised its target to $180 and also maintained outperform, while Canaccord reiterated Buy at $179. RBC price-target update
• Neutral Sentiment: Other target increases came with cautious ratings: JPMorgan and Citi moved to $170, UBS to $171, and Wells Fargo to $172, while retaining neutral or equal-weight stances. RBC sees valuation as attractive but notes a more conservative 2027 outlook. RBC valuation and outlook commentary
• Negative Sentiment: Management cautioned that growth may slow in 2027 and that competitors could take some share from Omnipod. Those forward-looking concerns may be outweighing the strong quarter and contributing to the stock’s decline. CEO comments on growth and competition

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.